Aequus Pharmaceuticals
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2820-200 Granville St, Vancouver, Britis...Phone Number
(604) 336-7906Website
www.aequuspharma.caRevenue
<$5 MillionStock Symbol
AQSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus was established in 2013, and is headquartered in British Columbia, Canada.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aequus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Aequus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Aequus Pharmaceuticals has new funding data
Product Launch: Get notified when Aequus Pharmaceuticals launches new products
Click to see if Aequus Pharmaceuticals had a recent Job posting/layoffs
Check out if Aequus Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Aequus Pharmaceuticals
Check if Aequus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Aequus Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Aequus Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Aequus Pharmaceuticals
Compare insights from companies similar to Aequus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aequus Pharmaceuticals
<$5M
11-50
Public
<$5M
2013
N/A
Company Profile Activity
Activity Insights
Aequus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aequus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aequus Pharmaceuticals.
Aequus Pharmaceuticals financials insights
Gather financial insights about Aequus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$1.9M
2021
Share Placement
$1M
2023
Debt
$300K
Aequus Pharmaceuticals Tech Stack
A closer look at the technologies used by Aequus Pharmaceuticals
Most Recent Scoops
Funding
Funding
Funding
Funding
Aequus Pharmaceuticals News & Media
2023-10-06 | TSXV:AQS | Press Release | Aequus Pharmaceuticals Inc - Stockhouse
(2023-10-06 | TSXV:AQS) Aequus Announces New Financing and Provides Launch Update of Zimed Preservative Free (Bimatoprost 0.03%)Aequus Grants Stock Options
VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces that it has granted incentive stock options (the “Options”) to certain directors, officers, employees, and consultants of the Company to purchase up to an aggregate of 2,775,000 common shares of the Company. These stock options are exercisable at a price of $0.03 per share, for a term of eight years, and vest in tranchesAequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)
VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America.Aequus Reports Third Quarter 2022 Financial Highlights
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (“Third Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Aequus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Aequus Pharmaceuticals Inc is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus was established in 2013, and is headquartered in British Columbia, Canada.... Read More
